Latest News and Press Releases

BIOTIE THERAPIES OYJ             PÖRSSITIEDOTE                  25.7.2011  klo 9.00 Biotien SYN120:n kliininen ohjelma etenee - kuvantamistutkimus käynnistynyt Johns Hopkins yliopiston...

B&B TOOLS Annual Report for the operating year 1 April 2010 - 31 March 2011 can now be downloaded from the following link. Attachment: B&B TOOLS Annual Report 2010/2011 Stockholm, 25 July 2011 B&B...

BIOTIE THERAPIES CORP.      STOCK EXCHANGE RELEASE       25 July 2011, at 9.00 a.m. Biotie Advances Clinical Program for SYN120 with Imaging Study at Johns Hopkins Center of Excellence Biotie today...

Delårsrapport Januari - juni 2011 ANDRA KVARTALET 2011 JÄMFÖRT MED 2010 Nettoomsättningen ökade med 40 procent till 670,9 MSEK (479,6). Rörelseresultat ökade med 44 procent till 14,7 MSEK...

Interim report January - June 2011 SECOND QUARTER 2011 COMPARED WITH 2010 · Net sales rose by 40 percent to SEK 670.9 million (479.6) · Operating profit improved by 44 percent to SEK 14.7...

DragonBack selects Orc for volatility trading on Asian markets For Immediate Release: Hong Kong, Sydney and Tokyo - Monday, July 25, 2011 - Orc Group AB (SSE: ORC), a leading provider of technology...

Sublinox approved in Canada The Canadian regulatory authority (Health Canada) has approved Sublinox for treatment of insomnia. Sublinox is a new and patented sublingual product with the well known...

Sublinox godkänd i Kanada Den kanadensiska läkemedelsmyndigheten (Health Canada) har godkänt Sublinox för behandling av sömnbesvär. Sublinox är en nytt patenterat sublingualt läkemedel med den...

Sublinox (Edluar) approved in Canada   Uppsala, Sweden, July 25 2011 - The insomnia drug Sublinox (Edluar) has been approved in Canada. Meda and its partner Valeant expect to begin the launch in the...

Sublinox (Edluar) godkänt i Kanada   Uppsala, 25 juli 2011 - Sömnmedlet Sublinox (Edluar) har godkänts för försäljning i Kanada. Meda och dess partner Valeant planerar att lansera Sublinox i Kanada...